Jpmorgan Chase & CO Black Diamond Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 20,248 shares of BDTX stock, worth $84,839. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,248
Previous 18,929
6.97%
Holding current value
$84,839
Previous $40,000
22.5%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding BDTX
# of Institutions
98Shares Held
41.3MCall Options Held
0Put Options Held
0-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.5MShares$44 Million0.02% of portfolio
-
Vestal Point Capital, LP New York, NY5.6MShares$23.5 Million0.73% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$18.6 Million0.91% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$13.5 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V82.73MShares$11.5 Million0.15% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $152M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...